Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia [ Studio sull'efficacia e la sicurezza di tre diversi dosaggi di Lais Ambrosia compresse in pazienti con rinocongiuntivite allergica al polline di Ambrosia]

Trial Profile

Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia [ Studio sull'efficacia e la sicurezza di tre diversi dosaggi di Lais Ambrosia compresse in pazienti con rinocongiuntivite allergica al polline di Ambrosia]

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2013

At a glance

  • Drugs Ragweed allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Lofarma S.p.A
  • Most Recent Events

    • 05 Oct 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 14 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top